Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | MPI | P34949 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6044162 | 0.98 | GLA (0.68) | GLAKDM4EL3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL1358701 | 0.89 | KDM4E (0.61) | GLAKDM4EL3MBTL1SMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL11543248 | 0.88 | GLA (0.60) | GLAKDM4EL3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL8616993 | 0.88 | KDM4E (0.59) | GLAKDM4EL3MBTL1SMN1; SMN2ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL3749224 | 0.88 | GLA (0.56) | GLAKDM4EL3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL1726737 | 0.86 | KDM4E (0.57) | GLAKDM4EL3MBTL1SMN1; SMN2GAA | |
| SCHEMBL5843494 | 0.86 | KDM4E (0.57) | GLAKDM4EL3MBTL1SMN1; SMN2GAA | |
| SCHEMBL30701340 | 0.86 | KDM4E (0.57) | GLAKDM4EL3MBTL1SMN1; SMN2GAA | |
| Hydrochloric Acid SCHEMBL5843429 | 0.84 | GLA (0.56) | GLAKDM4EL3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL11598668 | 0.84 | L3MBTL1 (0.77) | GLAKDM4EL3MBTL1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 634 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3814356-B1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ZHEJIANG VIMGREEN PHARMACEUTICALS LTD (CN) | 2026-03-11 | — | — | EP | claimed |
| EP-4182308-B1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARM SPA (IT) | 2024-09-04 | — | — | EP | claimed |
| CN-118201915-A | Pyridazinylamino derivatives as ALK5 inhibitors | 奇斯药制品公司 | 2024-06-14 | — | — | CN | claimed |
| CN-117777059-A | Preparation method of acrylamide compound | 深圳有为技术控股集团有限公司 | 2024-03-29 | — | — | CN | claimed |
| CN-111836801-B | Compounds for inhibiting TNIK and medical use thereof | 韩国化学硏究院 | 2024-02-02 | — | — | CN | claimed |
| CN-111051309-B | Triazolotriazine derivatives useful as A2A receptor antagonists | 浙江春禾医药科技有限公司 | 2023-05-26 | — | — | CN | claimed |
| EP-4182308-A1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2023-05-24 | — | — | EP | claimed |
| CN-116096719-A | Pyridazinylamino derivatives as ALK5 inhibitors | 奇斯药制品公司 | 2023-05-09 | — | — | CN | claimed |
| CN-114901665-A | Use of triazolotriazine derivatives for the treatment of diseases | 浙江春禾医药科技有限公司 | 2022-08-12 | — | — | CN | claimed |
| WO-2022013307-A1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-01-20 | — | — | WO | claimed |
| US-20030125370-A1 | 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | SUGEN, INC. | 2003-07-03 | — | — | US | claimed |
| EP-0980374-B1 | PHOSPHODIESTERASE 4-INHIBITING DIAZEPINOINDOLONES | PFIZER HOLDING FRANCE (FR) | 2003-02-12 | — | — | EP | claimed |
| WO-2002094833-A1 | NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2002-11-28 | — | — | WO | claimed |
| US-6239130-B1 | ASTHMA, ATOPIC DERMATITIS, RHEUMATOID ARTHRITIS, INFLAMMATORY BOWEL DISORDERS, PULMONARY HYPERTENSION, LIVER INJURY, BONE LOSS, SEPTIC SHOCK, OR MULTIPLE SCLEROSIS, | WARNER-LAMBERT COMPANY | 2001-05-29 | — | — | US | claimed |
| EP-0980374-A1 | PHOSPHODIESTERASE 4-INHIBITING DIAZEPINOINDOLONES | PARKE-DAVIS (FR) | 2000-02-23 | — | — | EP | claimed |
| EP-0678503-B1 | Delta-amino-gamma-hydroxy-omega-aryl alkanoic acid amides with enzyme especially renin inhibiting activities | NOVARTIS AG (CH) | 1999-09-01 | — | — | EP | claimed |
| WO-1998049169-A1 | PHOSPHODIESTERASE 4-INHIBITING DIAZEPINOINDOLONES | PARKE-DAVIS (FR) | 1998-11-05 | — | — | WO | claimed |
| WO-1998025884-A1 | FURTHER ANTHRAQUINONES WITH BIOLOGICAL ACTIVITY | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1998-06-18 | — | — | WO | claimed |
| WO-1996024587-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1996-08-15 | — | — | WO | claimed |
| US-3959191-A | Novel hydrophobic polyurethane foams | W. R. GRACE & CO. (US) | 1976-05-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125370-A1 | 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | DMPK, ADK, MAP3K20 | GLA 4413/4885KDM4E 931/4885L3MBTL1 4313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.